TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26244520

Group type: EXPERIMENTAL
Intervention: Tamsulosin 400 µg
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1167

Group type: EXPERIMENTAL
Intervention: Tamsulosin 400 µg and Nifedipine 30 mg
Number of subjects: 1167
Study: 24122181

Group type: EXPERIMENTAL
Intervention: Quinacrine (300 mg daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 22008301

Group type: EXPERIMENTAL
Intervention: HG plus maxillary acrylic biteplate (BP)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Headgear (HG)
Number of subjects: 131
Study: 17824846

Group type: EXPERIMENTAL
Intervention: CPAP (continuous positive airway pressure) treatment; duration: 1 month; n=12
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group; n=7
Number of subjects: 19
Study: 16837619

Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day for 3 months (Group S2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day for 3 months (Group S22)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day (Group S212)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 100 microg L-selenomethionine per day (Group S21)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day (Group S2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 200 microg L-selenomethionine per day (Group S222)
Number of subjects: 88
Study: 12570285

Group type: EXPERIMENTAL
Intervention: Sit-up training group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Curl-up training group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 11482709

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography of diastolic transmitral flow velocities
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dobutamine infusion at 10 mcg/kg/min
Number of subjects: 24
Study: 9575668

Group type: EXPERIMENTAL
Intervention: Group I (116 subjects with subjective symptoms)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Group II (72 subjects without subjective or objective symptoms)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (194 persons with normal EEG)
Number of subjects: 188
Study: 8097082

Group type: EXPERIMENTAL
Intervention: Zalcitabine (2.25 mg/d)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Zidovudine (500 to 1200 mg/d)
Number of subjects: 111
Study: 3709638

Group type: EXPERIMENTAL
Intervention: cadralazine 15 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: chlorthalidone 25 mg once daily
Number of subjects: 20
Study: 31699944

Group type: EXPERIMENTAL
Intervention: ARV therapy using fixed-dose combination (tenofovir, lamivudine, efavirenz)
Number of subjects: 75
Study: 28124288

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (I-CBT)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Monitoring, feedback, and support (I-MFS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Both I-CBT and I-MFS
Number of subjects: 174
Study: 26613606

Group type: EXPERIMENTAL
Intervention: Netupitant/palonosetron 300/0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palonosetron 0.5 mg
Number of subjects: 0
Study: 23799210

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate and magnesium citrate
Number of subjects: 181

Group type: COMPARATOR
Intervention: 4-liter split-dose polyethylene glycol (PEG)
Number of subjects: 181
Study: 22749961

Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulation
Number of subjects: 141

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 141
Study: 19772446

Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin
Number of subjects: 411

Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 411
Study: 17537207

Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping and ablation for right AMRT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Electroanatomical mapping and ablation for left AMRT
Number of subjects: 33
Study: 15350182

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CEE plus MPA (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CEE plus MPA
Number of subjects: 125

Group type: COMPARATOR
Intervention: Raloxifene 120 mg
Number of subjects: 125
Study: 11952434

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study: 9481634

Group type: COMPARATOR
Intervention: Formula (F)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Formula mixed with rice cereal (F + R)
Number of subjects: 14
Study: 8591079

Group type: EXPERIMENTAL
Intervention: FAM2 chemotherapy
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (no FAM2 chemotherapy)
Number of subjects: 314
Study: 2121487

Group type: EXPERIMENTAL
Intervention: Thrombolytic agents (streptokinase, t‐PA, APSAC)
Number of subjects: 0
Study: 90217

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31784747

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 170
Study: 31164489

Group type: EXPERIMENTAL
Intervention: IQOS packaging designs (three designs with varying links to Marlboro brand)
Number of subjects: 954
Study: 28831539

Group type: EXPERIMENTAL
Intervention: Screening for diabetes and cardiovascular risk assessment
Number of subjects: 139075

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 139075
Study: 25995276

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs) delivered biweekly to homes
Number of subjects: 1612

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNSs)
Number of subjects: 1612
Study: 22998014

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB‐FFP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Solvent/detergent (S/D‐FFP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Quarantine (Q‐FFP)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 293
Study: 21046070

Group type: EXPERIMENTAL
Intervention: maintenance treatment (initial optimal therapeutic doses continued throughout the study)
Number of subjects: 404

Group type: COMPARATOR
Intervention: dose-reduction group (initial optimal therapeutic doses continued for 4 or 26 weeks followed by a 50% dose reduction)
Number of subjects: 404
Study: 19496901

Group type: EXPERIMENTAL
Intervention: Thienopyridine administration (500 mg ticlopidine or 300 mg clopidogrel)
Number of subjects: 1036
Study: 17380456

Group type: EXPERIMENTAL
Intervention: Postoperative intra-iliac and hepatic arterial infusion chemotherapy (group I)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine vein chemotherapy (group II)
Number of subjects: 84
Study: 15499696

Group type: EXPERIMENTAL
Intervention: Gefitinib monotherapy (250 mg/day and 500 mg/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Gefitinib monotherapy
Number of subjects: 1000
Study: 11562798

Group type: EXPERIMENTAL
Intervention: Functional knee brace (SofTec, Bauerfeind)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standardized physical therapy program
Number of subjects: 46
Study: 9596249

Group type: EXPERIMENTAL
Intervention: Acetazolamide 1000 mg i.v.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg i.v.
Number of subjects: 9
Study: 7809342

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group psychotherapy (CBT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Experiential group psychotherapy (ET)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting-list control group (WCG)
Number of subjects: 39
Study: 3053888

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nadolol (compliant subgroup)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (compliant subgroup)
Number of subjects: 53
Study: 31753736

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS-ER) and topiramate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 29668634

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 566

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 566
Study: 28939307

Group type: EXPERIMENTAL
Intervention: Post-training FIFA 11+ exercise program
Number of subjects: 344

Group type: COMPARATOR
Intervention: Pre FIFA 11+ program alone (Control)
Number of subjects: 344
Study: 25140041

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 41
Study: 23312079

Group type: EXPERIMENTAL
Intervention: HP+ (high-sensory protein)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HC+ (high-sensory carbohydrate)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HP2 (low-sensory protein)
Number of subjects: 26

Group type: COMPARATOR
Intervention: LE (lower-energy drink)
Number of subjects: 26
Study: 21676230

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich beverage (PRB)
Number of subjects: 31
Study: 18631255

Group type: EXPERIMENTAL
Intervention: Once-daily fixed-dose combination tablet of abacavir and lamivudine (ABC/3TC FDC, Kivexa)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Twice-daily abacavir and lamivudine (ABC and 3TC)
Number of subjects: 94
Study: 17008617

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 3996

Group type: COMPARATOR
Intervention: CABG with CPB
Number of subjects: 3996
Study: 15536660

Group type: EXPERIMENTAL
Intervention: Medicated paste (petrolatum, 15% zinc oxide, 0.25% miconazole nitrate)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (non-medicated cream)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Medicated paste
Number of subjects: 35
Study: 10887758

Group type: EXPERIMENTAL
Intervention: Eating disorder diagnostic scale
Number of subjects: 367
Study: 9063546

Group type: COMPARATOR
Intervention: IV crystalloid after no phlebotomy (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IV crystalloid after phlebotomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-hoc analysis for phlebotomy group
Number of subjects: 20
Study: 7677801

Group type: EXPERIMENTAL
Intervention: intensive-course 5FU plus low-dose leucovorin (5FU 425 mg/m2 plus leucovorin 20 mg/m2 IV push daily for 5 days, courses repeated at 4- to 5-week intervals)
Number of subjects: 372

Group type: COMPARATOR
Intervention: weekly 5FU plus high-dose leucovorin (5FU 600 mg/m2 IV push plus leucovorin 500 mg/m2 as a 2-hour infusion weekly for 6 weeks, courses repeated every 8 weeks)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: intensive-course 5FU plus low-dose leucovorin
Number of subjects: 372

Group type: COMPARATOR
Intervention: weekly 5FU plus high-dose leucovorin
Number of subjects: 372
Study: 2801549

Group type: EXPERIMENTAL
Intervention: beta 1‐adrenergic blockade with optimal dose metoprolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 342620

Group type: EXPERIMENTAL
Intervention: 200 CCA units of vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 CCA units of vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subvirion vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole‐virus vaccines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 0
Study: 30949708

Group type: EXPERIMENTAL
Intervention: Lefamulin (intravenous and oral administration)
Number of subjects: 32
Study: 28333173

Group type: EXPERIMENTAL
Intervention: Submuscular breast augmentation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 26812510

Group type: EXPERIMENTAL
Intervention: Lower intake of total fat
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Lower intake of saturated fatty acids
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Frequent physical activity
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Weight reduction prior to cognition assessment
Number of subjects: 522
Study: 23823056

Group type: EXPERIMENTAL
Intervention: Cervical total disk arthroplasty with the Discover cervical disk prosthesis
Number of subjects: 32

Group type: COMPARATOR
Intervention: ACDF with a polyetheretherketone cage and plate
Number of subjects: 32
Study: 21677464

Group type: EXPERIMENTAL
Intervention: HAI FUDR/Dex plus IV Bev
Number of subjects: 22

Group type: COMPARATOR
Intervention: HAI FUDR/Dex alone (no Bev)
Number of subjects: 22
Study: 19537523

Group type: EXPERIMENTAL
Intervention: Rilmenidine dihydrogen phosphate (1.544 mg, equivalent to 1 mg rilmenidine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reference product (1.544 mg rilmenidine dihydrogen phosphate)
Number of subjects: 25
Study: 16403735

Group type: EXPERIMENTAL
Intervention: 1 g AAs/kg within the first 24 h
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 12 mL MEF x kg(‐1) x d(‐1) within the first 72 h
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study: 15569795

Group type: EXPERIMENTAL
Intervention: Ivermectin (200 microg/kg, single dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for 21 days)
Number of subjects: 31
Study: 11523759

Group type: EXPERIMENTAL
Intervention: Solitary cysticercus granuloma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management approach discussed
Number of subjects: 0
Study: 8720888

Group type: EXPERIMENTAL
Intervention: Electrochemical sensor (Alcomed 3010) for measuring end-tidal breath alcohol concentration (etAC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Electrochemical sensor (Alcomed 3010) for measuring etAC
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Electrochemical sensor (Alcomed 3010)
Number of subjects: 101
Study: 2021717

Group type: EXPERIMENTAL
Intervention: Early angiography plus appropriate intervention (coronary angioplasty in 169 cases, coronary grafting in 59)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Conservative care (403 patients, with 12 having angioplasty and 7 bypass grafting during initial admission)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Early angiography plus appropriate intervention
Number of subjects: 800

Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 800
Study: 6800507

Group type: EXPERIMENTAL
Intervention: Outpatient physiotherapy after medial meniscectomy
Number of subjects: 2

Group type: COMPARATOR
Intervention: No outpatient physiotherapy after medial meniscectomy
Number of subjects: 2
Study: 30278462

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (≥180 s)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) (≤60 s)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 540
Study: 28960745

Group type: EXPERIMENTAL
Intervention: Nonconditional cardiac implantable electronic devices (CIEDs) during MRI scans
Number of subjects: 178
Study: 25739671

Group type: EXPERIMENTAL
Intervention: 5‐FU/LV + irinotecan (experimental arm)
Number of subjects: 357

Group type: COMPARATOR
Intervention: 5‐FU/LV (control arm)
Number of subjects: 357
Study: 23473974

Group type: EXPERIMENTAL
Intervention: Empty can position
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Full can position
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (without shoulder pain)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Subacromial impingement group
Number of subjects: 28
Study: 21247820

Group type: EXPERIMENTAL
Intervention: Polymorphisms in AS3MT
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Polymorphisms in DNMT genes
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Noncoding AS3MT polymorphisms
Number of subjects: 533
Study: 19016074

Group type: EXPERIMENTAL
Intervention: Baerum-model like intervention (rapid-response outreach programme) for 6 months
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (prospective follow-up from 2002)
Number of subjects: 151
Study: 17440049

Group type: EXPERIMENTAL
Intervention: IgG antibodies to beta2-glycoprotein I (abeta2GPI)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IgG antibodies to prothrombin (aPT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IgG antibodies to annexin AV (aAnAV)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IgM antibodies to protein S
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lupus ratio of the dilute prothrombin time
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: LA-positive patients with abeta2GPI antibodies
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: LA-positive patients with aPT antibodies
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: LA-positive patients with IgG abeta2GPI and aAnAV antibodies
Number of subjects: 112
Study: 15345273

Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 82
Study: 11224480

Group type: EXPERIMENTAL
Intervention: r‐HuEPO (50 IU/kg three times per week)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 73
Study: 9521250

Group type: EXPERIMENTAL
Intervention: Deprenyl
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thioctic acid
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7532060

Group type: EXPERIMENTAL
Intervention: Intensive ablative maintenance (IM) program for 9 months
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intensive, short-term consolidation (IC) using 1 cycle of intermediate-dose Ara C plus AMSA and 1 cycle of HD-AraC/AMSA
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (refusals) who received no further treatment after early consolidation
Number of subjects: 122
Study: 2122506

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg.kg‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study: 342247

Group type: EXPERIMENTAL
Intervention: Piracetam (4,800 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 60
Study: 31804729

Group type: EXPERIMENTAL
Intervention: Autologous cultured fibroblasts (ACFs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (saline injections)
Number of subjects: 21
Study: 30813256

Group type: EXPERIMENTAL
Intervention: Tomato pomace extract (1 g)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Tomato pomace extract (2.5 g)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 28121184

Group type: EXPERIMENTAL
Intervention: Reduced-exertion high-intensity interval training (REHIT) - 8 weeks, three 10-min low-intensity cycling sessions/week with two 'all-out' 10-20-s sprints
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate-intensity walking - 8 weeks, five 30-min sessions/week at 40%-55% of heart-rate reserve
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both REHIT and moderate-intensity walking
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neither REHIT nor moderate-intensity walking
Number of subjects: 16
Study: 25834670

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 226

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 226
Study: 23846019

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1472

Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 1472
Study: 25214979

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine inhalation in addition to routine treatment (groups A2 and B1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nebulized normal saline apart from routine treatment (groups A1 and B2)
Number of subjects: 36
Study: 20003208

Group type: EXPERIMENTAL
Intervention: Culturally- and literacy-tailored diabetes self-management intervention (Latinos en Control)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 250
Study: 17206286

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study: 14720161

Group type: EXPERIMENTAL
Intervention: DC induction
Number of subjects: 37

Group type: COMPARATOR
Intervention: T shock
Number of subjects: 37
Study: 11727084

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication (LF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open fundoplication (OF)
Number of subjects: 60
Study: 8985267

Group type: EXPERIMENTAL
Intervention: Endoscopic rubber band ligation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Combination therapy (ligation + sclerotherapy)
Number of subjects: 47
Study: 8214740

Group type: EXPERIMENTAL
Intervention: Electric warming blanket
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bair Hugger
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Insulated Bair Hugger
Number of subjects: 55

Group type: COMPARATOR
Intervention: No hypothermia prevention (control group)
Number of subjects: 55
Study: 2872279

Group type: EXPERIMENTAL
Intervention: Alfentanil with neuromuscular blocking agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alfentanil without neuromuscular blocking agents
Number of subjects: 0
Study: 31125465

Group type: EXPERIMENTAL
Intervention: Immediate delivery (GRIT)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Delayed delivery with monitoring by conventional cardiotocography (CTG) (GRIT)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Computerized CTG (cCTG) only (GRIT and TRUFFLE)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: cCTG and ductus venosus (DV) Doppler (TRUFFLE)
Number of subjects: 741